The clinical community is intently watching the novel dual-action agent, a combined drug targeting both glucose metabolism and another incretin hormone. Initial trials suggest it may offer substantial gains in reducing body weight compared to traditional approaches, possibly representing a major breakthrough in the battle of obesity. More research